Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Bioactive Agents for the Treatment against Tuberculosis
share announcement

Bioactive Agents for the Treatment against Tuberculosis

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: 20 September 2024 | Viewed by 3006

Special Issue Editor

Prof. Dr. Fernando Rogério Pavan

E-Mail Website
Guest Editor
School of Pharmacy, São Paulo State University (UNESP), Araraquara-Jaú Road, Araraquara 148000-903, SP, Brazil
Interests: mycobacterium tuberculosis; new drugs; biological assays; antibiotics; antibiotics resistance
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis (MTB), which has, in the last three years during the COVID-19 pandemic, remained "slightly invisible". The new WHO report indicates the prevalence and a significant increase in active tuberculosis, as well as the incidence of cases of resistance to rifampicin and isoniazid. The World Health Organization indicates that urgent antimycobacterial agents must be studied, as the search for new molecules is still a great challenge.

This Special Issue aims to highlight the application of bioactive agents, synthesized (as biomacromolecules, peptides, conjugates, nanocomposites, etc.) agents, or promising isolates (such as toxins, proteins, lipids, enzymes, etc.) with high pharmacological and therapeutic activity against sensible and multi-drug-resistant MTB. Studies concerning administration methods as well as carriers are accepted Special Issue, as well as those related to their physicochemical characterization studies, pharmacological and enzymological parameters, drug release, biological activity and in vitro and/or in vivo studies. Reviews of current challenges and potential new drugs launched in recent years are also acceptable. It is hoped that the articles published in this Special Issue can solve the current challenges facing society related to the discovery and knowledge of drugs, as well as explore the advances in medicinal chemistry against MTB.

We look forward to receiving your contributions.

Prof. Dr. Fernando Rogério Pavan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobial activity
  • anti-inflammatory activity
  • biological activity
  • biomacromolecules
  • biomaterials
  • pharmaceutical biotechnology
  • drug delivery
  • infectious diseases
  • nanotechnology
  • pharmacy
  • pharmacology
  • therapeutics
  • toxins
  • venom

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 2071 KiB  
Article
TB/FLU-06E Influenza Vector-Based Vaccine in the Complex Therapy of Drug-Susceptible and Drug-Resistant Experimental Tuberculosis
by Anna-Polina S. Shurygina, Natalia V. Zabolotnykh, Tatiana I. Vinogradova, Maria L. Vitovskaya, Marine Z. Dogonadze, Kirill A. Vasilyev, Zhanna V. Buzitskaya, Petr K. Yablonskiy, Dmitriy A. Lioznov and Marina A. Stukova
Pharmaceutics 2024, 16(7), 857; https://doi.org/10.3390/pharmaceutics16070857 - 25 Jun 2024
Viewed by 607
Abstract
The steady rise of drug-resistant tuberculosis (TB), which renders standard therapy regimens ineffective, necessitates the development of innovative treatment approaches. Immunotherapeutic vaccines have the potential to effectively regulate the anti-TB immune response and enhance the efficacy of anti-TB treatment. In the present study, [...] Read more.
The steady rise of drug-resistant tuberculosis (TB), which renders standard therapy regimens ineffective, necessitates the development of innovative treatment approaches. Immunotherapeutic vaccines have the potential to effectively regulate the anti-TB immune response and enhance the efficacy of anti-TB treatment. In the present study, we aimed to evaluate the potency of the mucosal vector vaccine TB/FLU-06E as part of a complex treatment regimen for drug-susceptible (DS) or drug-resistant (DR) tuberculosis in C57BL/6 mice. Incorporating TB/FLU-06E into the treatment protocol significantly increased the effectiveness of therapy for both forms of tuberculosis. It was evidenced by higher survival rates and reduced pulmonary bacterial load (1.83 lg CFU for DS tuberculosis and 0.93 lg CFU for DR tuberculosis). Furthermore, the treatment reduced pathomorphological lesions in the lungs and stimulated the local and systemic T-helper 1 (Th1) and cytotoxic T- lymphocyte (CTL) anti-TB immune responses. Thus, therapeutic immunization with the TB/FLU-06E vaccine significantly enhances the efficacy of tuberculosis treatment, which is particularly important in DR tuberculosis. Full article
(This article belongs to the Special Issue Bioactive Agents for the Treatment against Tuberculosis)

Review

Jump to: Research

24 pages, 3366 KiB  
Review
Advances in Diagnostics and Drug Discovery against Resistant and Latent Tuberculosis Infection
by Christian Shleider Carnero Canales, Jessica Marquez Cazorla, André Henrique Furtado Torres, Eloise T. Monteiro Filardi, Leonardo Delello Di Filippo, Paulo Inácio Costa, Cesar Augusto Roque-Borda and Fernando Rogério Pavan
Pharmaceutics 2023, 15(10), 2409; https://doi.org/10.3390/pharmaceutics15102409 - 30 Sep 2023
Cited by 8 | Viewed by 1973
Abstract
Latent tuberculosis infection (LTBI) represents a subclinical, asymptomatic mycobacterial state affecting approximately 25% of the global population. The substantial prevalence of LTBI, combined with the risk of progressing to active tuberculosis, underscores its central role in the increasing incidence of tuberculosis (TB). Accurate [...] Read more.
Latent tuberculosis infection (LTBI) represents a subclinical, asymptomatic mycobacterial state affecting approximately 25% of the global population. The substantial prevalence of LTBI, combined with the risk of progressing to active tuberculosis, underscores its central role in the increasing incidence of tuberculosis (TB). Accurate identification and timely treatment are vital to contain and reduce the spread of the disease, forming a critical component of the global strategy known as “End TB.” This review aims to examine and highlight the most recent scientific evidence related to new diagnostic approaches and emerging therapeutic treatments for LTBI. While prevalent diagnostic methods include the tuberculin skin test (TST) and interferon gamma release assay (IGRA), WHO’s approval of two specific IGRAs for Mycobacterium tuberculosis (MTB) marked a significant advancement. However, the need for a specific test with global application viability has propelled research into diagnostic tests based on molecular diagnostics, pulmonary immunity, epigenetics, metabolomics, and a current focus on next-generation MTB antigen-based skin test (TBST). It is within these emerging methods that the potential for accurate distinction between LTBI and active TB has been demonstrated. Therapeutically, in addition to traditional first-line therapies, anti-LTBI drugs, anti-resistant TB drugs, and innovative candidates in preclinical and clinical stages are being explored. Although the advancements are promising, it is crucial to recognize that further research and clinical evidence are needed to solidify the effectiveness and safety of these new approaches, in addition to ensuring access to new drugs and diagnostic methods across all health centers. The fight against TB is evolving with the development of more precise diagnostic tools that differentiate the various stages of the infection and with more effective and targeted treatments. Once consolidated, current advancements have the potential to transform the prevention and treatment landscape of TB, reinforcing the global mission to eradicate this disease. Full article
(This article belongs to the Special Issue Bioactive Agents for the Treatment against Tuberculosis)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop